{"id":390635,"date":"2018-06-28T00:00:00","date_gmt":"2018-06-28T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0037-2018-biopharma-overactive-bladder-treatment-algorithms-claims-data-analysis-us-2018\/"},"modified":"2026-05-10T11:37:00","modified_gmt":"2026-05-10T11:37:00","slug":"algoim0037-2018-biopharma-overactive-bladder-treatment-algorithms-claims-data-analysis-us-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0037-2018-biopharma-overactive-bladder-treatment-algorithms-claims-data-analysis-us-2018\/","title":{"rendered":"Overactive Bladder | Treatment Algorithms | Claims Data Analysis | US | 2018"},"content":{"rendered":"<p><strong>MARKET OUTLOOK<\/strong><\/p>\n<p>The well-established antimuscarinic drug class dominates the overactive bladder (<abbr data-original-title=\"overactive bladder\" title=\"\">OAB<\/abbr>) therapy market, and the continued generic erosion of these agents will be the most significant constraint on the market\u2019s future growth. However, for patients in whom these drugs are not effective, the options are limited. The two most recent market entrants, Astellas\u2019s Myrbetriq and Allergan\u2019s Botox (both of which offer alternative\u00a0<abbr data-original-title=\"mechanism of action\" title=\"\">MOA<\/abbr>s), have enjoyed strong growth in this market driven by a need for therapies effective in patients who are refractory to the antimuscarinics, by direct-to-consumer promotion, and by life-cycle management strategies used\u00a0by their developers.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What patient share do key therapies and brands garner by line of therapy in newly diagnosed\u00a0<abbr data-original-title=\"overactive bladder\" title=\"\">OAB<\/abbr>\u00a0patients? What are the quarterly trends in prescribing among recently treated and new diagnosed\u00a0<abbr data-original-title=\"overactive bladder\" title=\"\">OAB<\/abbr>\u00a0patients?<\/li>\n<li>How have more-recent market entrants such as Myrbetriq and Botox been integrated into the\u00a0<abbr data-original-title=\"overactive bladder\" title=\"\">OAB<\/abbr>\u00a0treatment algorithm?<\/li>\n<li>What proportion of\u00a0<abbr data-original-title=\"overactive bladder\" title=\"\">OAB<\/abbr>\u00a0patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?<\/li>\n<li>What percentage of\u00a0<abbr data-original-title=\"overactive bladder\" title=\"\">OAB<\/abbr>\u00a0patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients with\u00a0<abbr data-original-title=\"overactive bladder\" title=\"\">OAB<\/abbr>?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION:<\/strong><\/p>\n<p><em>Treatment Algorithms: Claims Data Analysis<\/em>\u00a0provides detailed analysis of brand usage across different lines of therapy using real-world patient-level claims data so that clients can accurately assess their source of business and quantify areas of opportunity for increasing their brand share.<\/p>\n<p><strong>Geographies:\u00a0<\/strong>United States<\/p>\n<p><strong>Real-world data:\u00a0<\/strong>Longitudinal patient-level claims data analysis<\/p>\n<p><strong>Key drugs covered:<\/strong>\u00a0Botox, Myrbetriq, oxybutynin,\u00a0Vesicare<\/p>\n<p><strong>Key analysis provided:<\/strong><\/p>\n<ul>\n<li>Brand use across longitudinal patient sample.<\/li>\n<li>Newly diagnosed patient analysis.<\/li>\n<li>Treatment initiation and progression.<\/li>\n<li>Line of therapy analysis.<\/li>\n<li>Combination therapy analysis.<\/li>\n<li>Source of business for recently treated patients.<\/li>\n<li>Persistency and compliance analysis.<\/li>\n<li>Product-level patient flowcharts.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-390635","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-overactive-bladder","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390635","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390635\/revisions"}],"predecessor-version":[{"id":393759,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390635\/revisions\/393759"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390635"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}